Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 8,143 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Knee Osteoarthritis
Interventions: ENGAGE; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteers
Interventions: simufilam; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium (Lipitor); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Neonatal Abstinence Syndrome
Interventions: Human Milk, Standard of Care; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Up to 48 Hours
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Plaque Psoriasis
Interventions: ORKA-001 Induction Dose, Placebo, ORKA-001 Maintenance Dose; Drug · Other
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Fountain Valley, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Generalized Myasthenia Gravis
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Healthy Volunteers
Interventions: Lenvatinib 10 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Aggression, Self-injurious Behavior
Interventions: Trad FCT, Mult FCT, Mult FCT + Stimulus Fading; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: BH4 Deficiency, Hyperphenylalaninemia
Interventions: PTC923; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 12 Months and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Dallas, Texas • Salt Lake City, Utah + 1 more

Conditions: Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions: Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test; Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 215 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer
Interventions: Fludarabine, Cyclophosphamide, Young TIL, Aldesleukin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: Predictive Low Glucose Suspend Algorithm ON, Predictive Low Glucose Suspend Algorithm OFF; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 46 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Asthma
Interventions: Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg, Indacaterol 75 mcg, Indacaterol 150 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 9 more

Conditions: Metastasis
Interventions: THOR-707, Checkpoint inhibitor, anti-EGFR antibody; Drug
Lead sponsor: Synthorx, Inc, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more

Conditions: Glioblastoma
Interventions: Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab, Temozolomide, Poly-ICLC; Radiation · Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Diabetes Mellitus
Interventions: Optimized Shoulder Movement Program, ADA Guideline Instructed; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Epilepsy
Interventions: UPLIFT (Using Practice and Learning to Increase Favorable Thoughts), BOOST (Bringing Out Our Strength Together); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Vestibular Disorder
Interventions: Vestibular training using VR followed by Control, Control followed by Vestibular training using VR; Device
Lead sponsor: Clarkson University; Other
Eligibility: 55 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Potsdam, New York

Conditions: Acute Kidney Injury, Liver Injury, Inflammation
Interventions: Blue light; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pediatric Obesity
Interventions: Intervention by Clinicians, Usual Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 3 Years to 11 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Itasca, Illinois

Conditions: Cognitive Impairment, Mild, Cognitive Decline
Interventions: Walking conversational reminiscence; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 65 Years to 110 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Occupational Therapy-Delivered Cognitive Behavioral Therapy for Symptomatic Knee Osteoarthritis

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

Clinical Trial to Decrease Length of Stay in Infants With Neonatal Abstinence Syndrome With an Exclusive Human Milk Diet

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Refinements of Functional Communication Training

A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Diabetic Shoulder Mobility

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Telephone-Based Support Programs for People With Epilepsy

Concurrent Vestibular Activation and Postural Training Using Virtual Reality

Blue Light Therapy for Liver Surgery

Population Effects of MI on Pediatric Obesity in Primary Care

Efficacy of a Multimodal Brain Health Intervention for Older African Americans